Background Dupilumab is a fully human anti–interleukin-4 receptor α monoclonal antibody
that blocks both interleukin-4 and interleukin-13 signaling. We assessed its efficacy and …

Severe or therapy-resistant asthma is increasingly recognised as a major unmet need. A
Task Force, supported by the European Respiratory Society and American Thoracic Society, …

Background Elevated numbers of blood eosinophils are a risk factor for asthma exacerbations.
Reslizumab is a humanised anti-interleukin 5 monoclonal antibody that disrupts …

Rationale: Bronchial thermoplasty (BT) is a bronchoscopic procedure in which controlled
thermal energy is applied to the airway wall to decrease smooth muscle. Objectives: To …

Rationale: Eosinophilic asthma is a phenotype of asthma characterized by the persistence
of eosinophils in the airways. IL-5 is involved in the activation and survival of eosinophils. …

Rationale: The Severe Asthma Research Program cohort includes subjects with persistent
asthma who have undergone detailed phenotypic characterization. Previous univariate …

BACKGROUND: Severe asthma causes the majority of asthma morbidity. Understanding
mechanisms that contribute to the development of severe disease is important. OBJECTIVE: …

Background Dupilumab is a fully human anti–interleukin-4 receptor α monoclonal antibody
that blocks both interleukin-4 and interleukin-13 signaling. Its effectiveness in reducing oral …

Background Dupilumab, a fully human anti-interleukin-4 receptor α monoclonal antibody,
inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated inflammation…

Asthma is a common disease with a complex risk architecture including both genetic and
environmental factors. We performed a meta-analysis of North American genome-wide …